Product Description
RMC-035 is being developed by Guard Therapeutics for the treatment of patients with prevention and treatment of acute kidney injury (AKI) in patients undergoing cardiac surgery. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04829916?term=RMC-035&draw=2&rank=1)
Mechanisms of Action: a1m Analogue
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Guard Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, Czech Republic, Germany, Spain
Active Clinical Trial Count: 4
Highest Development Phases
Phase 2: Acute Kidney Injury|Other
Phase 1: Dyslipidemia|Hyperglycemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 24-ROS-07 | P2 |
Unknown Status |
Unknown |
2025-11-30 |
|
| POINTER | P2 |
Recruiting |
Other |
2025-10-30 |
|
| AKITA | P2 |
Active, not recruiting |
Acute Kidney Injury |
2023-09-09 |
|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Hyperglycemia|Dyslipidemia |
2018-08-24 |